single2MG
GHRP-6
2MG Protocol
GHRP-6 2MG
Injection Freq.
Inject three times daily
Cycle Sched.
8–12 weeks; rotate injection sites to prevent tissue irritation
Reconstitution
3.0 mL BAC water
Supports lean-mass gain and fat reduction via GH/IGF-1 signaling
Improved recovery and sleep architecture (more slow-wave sleep described)
Appetite stimulation (may aid weight-gain goals)
Cytoprotective/tissue-protective effects in preclinical models
Joint/connective-tissue support via collagen and repair signaling
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 100 mcg | 15 |
| 2 | Weeks 3–4 | 200 mcg | 30 |
| 3 | Weeks 5–12 | 300 mcg | 45 |
Inject three times daily
8–12 weeks; rotate injection sites to prevent tissue irritation
GHRP-6 is positioned as a synthetic agonist of the growth hormone secretagogue (ghrelin) receptor, producing sharp, episodic growth hormone pulses from pituitary somatotrophs. The protocol notes a second endocrine feature: by attenuating somatostatin’s inhibitory tone, GHRP-6 can amplify the magnitude of GH release while still allowing normal feedback loops to constrain excessive exposure. In addition, the page describes non-endocrine cytoprotective activity via CD36 receptor interactions on muscle and immune cells. This CD36-linked pathway is associated with activation of cell-survival signaling (including PI3K/Akt), which may help tissues resist oxidative stress and inflammation in experimental models. Taken together, GHRP-6 is described as both an endocrine pulse generator (GH/IGF-1 axis) and a broader tissue-protective signal that could contribute to recovery-oriented research outcomes.
Transient mild increases in cortisol/ACTH
Increased appetite
Water retention
Injection-site reactions (redness/itching/swelling)
Transient dizziness or flushing shortly after injection
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)